4.7 Meeting Abstract

Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S819-S819

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.08.153

Keywords

-

Categories

Funding

  1. Merck Sharp Dohme Corp.

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available